Induction of CTL Responses Using Antibody Targeted HLA Class I Peptide Complexes
Author Information
Author(s): Savage P, Cowburn P, Clayton A, Man S, McMichael A, Lemoine N, Epenetos A, Ogg G
Primary Institution: Alexis Biotechnology
Hypothesis
Can a two-step antibody delivery system effectively induce specific cytotoxic T cell responses from unselected populations of PBMCs?
Conclusion
The study demonstrates that antibody-targeted HLA class I/peptide complexes can effectively stimulate specific cytotoxic T cell responses in vitro.
Supporting Evidence
- The targeted HLA-class I/peptide complexes remained on the surface of B cells for over 72 hours.
- Up to 2.99% of CD8+ T cells were shown to be specific to the targeted complexes.
- A greater than five-fold increase in tetramer positive cells was observed in most volunteers after stimulation.
Takeaway
Scientists are trying to help the body fight cancer by teaching immune cells to recognize and attack cancer cells using special proteins.
Methodology
The study used a two-step biotin-streptavidin antibody targeting system to attach HLA-class I/peptide complexes to B cells, followed by in vitro stimulation of PBMCs.
Potential Biases
Potential for uncontrolled CTL expansion with intravenous administration of HLA class I complexes.
Limitations
There is considerable variation in the level of CTL responses produced from different individuals.
Participant Demographics
Healthy volunteers and melanoma patients, specifically HLA-A2 positive.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website